Parag Gandhi, MD
Ophthalmology · Rosedale, MDNPI 1689611691
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $78,973 of the $105,874 with a category attached, or 74.6%. Amgen accounts for 83.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $38,406 and has fallen 98.8% since, to $475 in 2025. Among ophthalmology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $641.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$88K
- Synthes GmbH$9K
- Genentech USA, Inc.$8K
- Galderma Laboratories, L.p.$222
- AbbVie$154
- ANI Pharmaceuticals, Inc.$125
- plus $304 from 5 others
What the payments were for
- Consulting fees$6,2006%
- Speaking & faculty fees$78,97375%
- Travel & lodging$14,26613%
- Food & beverage$6,4196%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 129 | $87,926 |
| Synthes GmbH | 13 | $9,248 |
| Genentech USA, Inc. | 6 | $7,896 |
| Galderma Laboratories, L.p. | 7 | $222 |
| AbbVie(2 entities) | 2 | $154 |
| ANI Pharmaceuticals, Inc. | 2 | $125 |
| Sight Sciences, Inc. | 1 | $104 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $95 |
| Johnson & Johnson | 2 | $72 |
| Shire North American Group Inc | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$85,507
- Enspryng$7,839
- OMNI(R) SURGICAL SYSTEM (US)$104
How this compares
$105,874 in reported general payments places this provider in the 95th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 68 | $550 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Rosedale
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Lisa FeulnerBel Air$434K
- Allen HuHagerstown$379K
- Susan BresslerLutherville$341K
- Renee BovelleGlenn Dale$292K
- Neil BresslerBaltimore$265K
- Scott LaborwitTowson$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.